PT  - JOURNAL ARTICLE
AU  - Francis Lee
AU  - Daniel Sheeler
AU  - Anna Hotton
AU  - Natascha Del Vecchio
AU  - Rey Flores
AU  - Kayo Fujimoto
AU  - Nina Harawa
AU  - John A. Schneider
AU  - Aditya S. Khanna
TI  - Stimulant Use Interventions May Strengthen ‘Getting to Zero’ Initiatives in Illinois: Insights from a Modeling Study
AID  - 10.1101/2021.09.22.21263980
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.22.21263980
4099  - http://medrxiv.org/content/early/2021/09/23/2021.09.22.21263980.short
4100  - http://medrxiv.org/content/early/2021/09/23/2021.09.22.21263980.full
AB  - Objective(s) Young Black men who have sex with men (YBMSM) are a key population identified in the Illinois Getting to Zero (GTZ) initiative who have experienced disproportionate HIV incidence. Rising stimulant use has been determined to impede the effectiveness of ART and pre-exposure prophylaxis for suppressing HIV transmission in populations. This modeling study explores the impact of stimulant use on HIV incidence among YBMSM – given the limited development of dedicated or culturally appropriate interventions for this population – and assesses the impact of these interventions on downstream HIV transmission in the context of achieving GTZ goals.Methods A previously developed agent-based network model (ABNM), calibrated using data for YBMSM in Illinois, was extended to incorporate the impact of stimulant use (methamphetamines, crack/cocaine, and ecstasy) on sexual networks and engagement in HIV treatment and prevention continua. The model simulated the impact of a residential behavioral intervention (BI) for reducing stimulant dependency and an outpatient biomedical intervention (mirtazapine) for treating methamphetamine dependence on improved engagement in the HIV treatment and prevention continua. The downstream impact of these interventions on population-level HIV incidence was the primary intervention outcome.Results Baseline simulated annual HIV incidence in the ABNM was 6.9(95% CI: 6.83,7.04) per 100 person years (py) and 453 (95% CI: 445.9,461.2) new infections annually. A residential targeted to 25% of stimulant users yielded a 27.1% decline in the annual number of new infections. Initiating about 50% of methamphetamine users on mirtazapine reduced the overall HIV incidence by about 11%. A 25% increase in antiretroviral treatment (ART) and preexposure prophylaxis (PrEP) uptake in the non-stimulant using YBMSM population combined with a 25% uptake of BI for stimulant users produces an HIV incidence consistent with HIV elimination targets (about 200 infections/year) identified in the GTZ initiative.Conclusions Targeted behavioral and biomedical interventions to treat stimulant dependency are likely to provide additive benefits to expanding ART and PrEP uptake for everyone in accomplishing GTZ initiatives for HIV elimination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH R01 DA 039934 and R03 DA 049662 and T32DA043469 and and the Providence/Boston Center for AIDS Research (P30AI042853). NH received additional support from the California HIV/AIDS Research Program (CHRP) OS17-LA-003 (PI Harawa) and the UCLA Clinical and Translational Science Institute (CTSI) NIH/NCATS grant UL1-TR001881 (PI Dubinett) and by the Center for HIV Identification Prevention and Treatment (CHIPTS) NIMH grant P30MH058107 (PI Shoptaw). This work was completed in part with resources provided by the University of Chicago Research Computing Center and the Center for Computation and Visualization at Brown University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Exemption was obtained from the Institutional Review Board at Brown University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll computer code and parameters needed to replicate the model are available in a public GitHub repository. https://github.com/khanna7/BARS/tree/substance-use